- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT02171533
Relative Bioavailability of Single Oral Doses of Dabigatran Etexilate With or Without Oral Administration of Verapamil in Two Different Dosages in Healthy Male and Female Volunteers
Relative Bioavailability of Single Oral Doses of 150 mg Dabigatran Etexilate With or Without Oral Administration of Verapamil in Two Different Dosages (240 mg and 480 mg Daily) (Open-label, Fixed-sequence Design), and Relative Bioavailability of Single Oral Doses of 150 mg Dabigatran Etexilate Given With or Without Single Oral Doses of 120 mg (IR) or 240 mg (ER) of Verapamil Administered at Different Time Points Relative to Dabigatran Etexilate Dosing in Healthy Male and Female Volunteers (Open-label, Randomised, Five-way Crossover Design, Phase I Study)
Přehled studie
Postavení
Podmínky
Intervence / Léčba
Typ studie
Zápis (Aktuální)
Fáze
- Fáze 1
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion criteria:
- Healthy males and females according to the following criteria: Based upon a complete medical history, including the physical examination, vital signs (blood pressure (BP), pulse rate (PR)), 12-lead electrocardiogram (ECG), clinical laboratory tests
- Age ≥18 and ≤55 years
- Body mass index (BMI) ≥18.5 and BMI ≤29.9 kg/m2
- Signed and dated written informed consent prior to admission to the study in accordance with GCP and the local legislation
Exclusion criteria:
- Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
- Relevant surgery of gastrointestinal tract
- History of any bleeding disorder or acute blood coagulation defect
- Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
- History of relevant orthostatic hypotension, fainting spells or blackouts
- Chronic or relevant acute infections
- History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator
- Pulse rate below 50 bpm and or systolic blood pressure <90 mm Hg at screening. ECG: PR >170 ms (Part 1), AV block ≥1st degree (Part 2) at screening
- Use of drugs which might reasonably influence the results of the trial based on the knowledge at the time of protocol preparation within four weeks prior to administration or during the trial, especially intake of medication, which influences the blood clotting, i.e., acetylsalicylic acid, cumarin etc.
- Participation in another trial with an investigational drug within two months prior to administration or during the trial
- Smoker (more than 15 cigarettes or 3 cigars or 3 pipes per day)
- Alcohol abuse (more than 60 g/day for men and more than 40 g/day for women)
- Drug abuse
- Blood donation (more than 100 mL within four weeks prior to administration or during the trial)
- Excessive physical activities (within one week prior to administration or during the trial)
- Any laboratory value outside the reference range that is of clinical relevance
- Planned surgeries within four weeks following the end-of study examination
The subject is not able to understand and comply with protocol requirements, instructions, protocol-stated restrictions and dietary regimen of study centre
For male subjects:
Male subjects who do not agree to minimise the risk of female partners becoming pregnant from the first dosing day until 3 months after the completion of the post study medical. Acceptable methods of contraception comprises barrier contraception and a medically accepted contraceptive method for the female partner (intra-uterine device with spermicide, hormonal contraceptive since at least two month)
For female subjects:
- Pregnancy / positive pregnancy test, or planning to become pregnant during the study or within 1 month of study completion
- No adequate contraception during the study and until 1 month of study completion, i.e. implants, injectables, combined oral contraceptives, IUD (intrauterine device), sexual abstinence (for at least 1 month prior to enrolment), vasectomised partner (vasectomy performed at least 1 year prior to enrolment), or surgical sterilisation (incl. hysterectomy). Females, who have not a vasectomised partner, are not sexually abstinent or surgically sterile will be asked to additionally use barrier contraception methods (e.g. condom, diaphragm with spermicide)
- Lactation period
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Crossover Assignment
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
---|---|
Experimentální: Fixed sequence
Treatments will be given in a fixed sequence
|
|
Experimentální: Crossover
Treatments will be given in randomized sequences
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Časové okno |
---|---|
AUC0-infinity (area under the concentration-time curve of total dabigatran over the time interval from 0 extrapolated to infinity)
Časové okno: up to 107 hours
|
up to 107 hours
|
Cmax (maximum measured concentration of total dabigatran)
Časové okno: up to 107 hours
|
up to 107 hours
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
AUC0-infinity (area under the concentration-time curve of free dabigatran over the time interval from 0 extrapolated to infinity)
Časové okno: up to 107 hours
|
up to 107 hours
|
|
Cmax (maximum measured concentration of free dabigatran)
Časové okno: up to 107 hours
|
up to 107 hours
|
|
AUC0-infinity (area under the concentration-time curve of verapamil over the time interval from 0 extrapolated to infinity)
Časové okno: up to 107 hours
|
up to 107 hours
|
|
Cmax (maximum measured concentration of verapamil)
Časové okno: up to 107 hours
|
up to 107 hours
|
|
AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point)
Časové okno: up to 107 hours
|
up to 107 hours
|
|
AUC0-24 (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to 24 h after the administration)
Časové okno: up to 107 hours
|
up to 107 hours
|
|
tmax (time from dosing to the maximum concentration of the analyte in plasma)
Časové okno: up to 107 hours
|
up to 107 hours
|
|
λz (terminal rate constant in plasma)
Časové okno: up to 107 hours
|
up to 107 hours
|
|
t1/2 (terminal half-life of the analyte in plasma)
Časové okno: up to 107 hours
|
up to 107 hours
|
|
MRTpo (mean residence time of the analyte in the body after oral administration)
Časové okno: up to 107 hours
|
up to 107 hours
|
|
CL/F (apparent clearance of the analyte in the plasma after extravascular administration)
Časové okno: up to 107 hours
|
up to 107 hours
|
|
Vz/F (apparent volume of distribution during the terminal phase λz following an extravascular dose)
Časové okno: up to 107 hours
|
up to 107 hours
|
|
AUCτ,ss (area under the concentration-time curve of verapamil within the uniform dosing interval τ)
Časové okno: up to 107 hours
|
up to 107 hours
|
|
AUC0-tz,ss (area under the concentration-time curve of verapamil from the time point 0 after the last dose at steady state to the last quantifiable analyte plasma concentration within the uniform dosing interval τ)
Časové okno: up to 107 hours
|
up to 107 hours
|
|
Cmax,ss (maximum concentration of verapamil at steady state)
Časové okno: up to 107 hours
|
up to 107 hours
|
|
tz,ss (time of last measureable concentration of verapamil within the dosing interval τ at steady state)
Časové okno: up to 107 hours
|
up to 107 hours
|
|
tmax,ss (time from last dosing to the maximum concentration of verapamil at steady state on day 4)
Časové okno: up to 107 hours
|
up to 107 hours
|
|
CL/F,ss (apparent clearance of verapamil at steady state after extravascular multiple dose administration)
Časové okno: up to 107 hours
|
up to 107 hours
|
|
Cmin,ss (minimum measured concentration of verapamil at steady state over a uniform dosing interval τ)
Časové okno: up to 107 hours
|
up to 107 hours
|
|
tmin,ss (time from last dosing to the minimum concentration of verapamil at steady state over a uniform dosing interval τ)
Časové okno: up to 107 hours
|
up to 107 hours
|
|
Cpre,ss (predose concentration of verapamil at steady state immediately before administration of the next dose)
Časové okno: up to 107 hours
|
up to 107 hours
|
|
Cavg (Average concentration of verapamil at steady state)
Časové okno: up to 107 hours
|
up to 107 hours
|
|
MRTpo,ss (mean residence time of verapamil in the body at steady state after oral administration)
Časové okno: up to 107 hours
|
up to 107 hours
|
|
Vz/F,ss (apparent volume of distribution during the terminal phase λz at steady state following an extravascular administration)
Časové okno: up to 107 hours
|
up to 107 hours
|
|
Ae0-24 (amount of dabigatran that is eliminated in urine from the time interval 0-24h)
Časové okno: up to 107 hours
|
up to 107 hours
|
|
fe0-24 (fraction of administered drug excreted unchanged in urine from time point 0- 24h)
Časové okno: up to 107 hours
|
up to 107 hours
|
|
CLR0-24 (renal clearance of dabigatran from the time point 0 until the time point 24h )
Časové okno: up to 107 hours
|
up to 107 hours
|
|
AUEC0-24 (area under the effect curve)
Časové okno: up to 107 hours
|
for ecarin clotting time and thrombin time
|
up to 107 hours
|
ERmax (maximum effect ratio)
Časové okno: up to 107 hours
|
for ecarin clotting time and thrombin time
|
up to 107 hours
|
Occurence of Adverse Events
Časové okno: within 5 days after last drug administration
|
within 5 days after last drug administration
|
|
Assessment of Tolerability by investigator
Časové okno: within 5 days after last drug administration
|
within 5 days after last drug administration
|
Spolupracovníci a vyšetřovatelé
Sponzor
Publikace a užitečné odkazy
Užitečné odkazy
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia
Primární dokončení (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Odhad)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Odhad)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
- Fyziologické účinky léků
- Molekulární mechanismy farmakologického působení
- Látky proti arytmii
- Vazodilatační činidla
- Inhibitory enzymů
- Inhibitory proteázy
- Membránové transportní modulátory
- Hormony a látky regulující vápník
- Antitrombiny
- Inhibitory serinových proteináz
- Antikoagulancia
- Blokátory vápníkových kanálů
- Dabigatran
- Verapamil
Další identifikační čísla studie
- 1160.74
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na Zdravý
-
University of BernUniversity Hospital Inselspital, BerneDokončenoNeuroscience of Dreaming, HealthŠvýcarsko
-
University of ZurichDokončenoOutcome Assessment, Health CareŠvýcarsko
-
University of Colorado, DenverEunice Kennedy Shriver National Institute of Child Health and Human Development... a další spolupracovníciAktivní, ne náborPreventivní zdravotní služby (PREV HEALTH SERV)Spojené státy
-
Queens College, The City University of New YorkNáborZveřejnění článků předložených American Journal of Public HealthSpojené státy
-
Kliniek ViaSanaSt. Anna Ziekenhuis, Geldrop, NetherlandsDokončenoBolest | Užívání opioidů | Totální náhrada kolena | Aplikace E-healthHolandsko
-
Istanbul University - Cerrahpasa (IUC)NáborKardiochirurgie, Srdeční chirurgie, Výuka propouštění, Ošetřovatelství, Telenutriční péče, m-Health, Kvalita života, ZotaveníKrocan
-
FIDMAG Germanes HospitalàriesUniversity of BarcelonaZatím nenabírámePorucha duševního zdraví | Duševní zdraví wellness 1 | Role sestry | Care Acceptor, Health | Vztah, sestra pacienta
-
University of AarhusRegion MidtJylland Denmark; Tryg Danmark; Randers Municipality, DenmarkNeznámýKardiovaskulární onemocnění | Podpora zdraví | Duševní zdraví | Fyzická nečinnost | Self-reported Quality of HealthDánsko
-
Yorkshire Ambulance Service NHS TrustUniversity of BradfordZatím nenabírámeTestování Point of Care | Klinické rozhodování | Komunitní urgentní a pohotovostní péče | Allied Health Professional
-
4Life Research, LLCDokončenoSin Health | Hydratace pleti | Kožní vrásky | Kožní porfyriny | Červené skvrny na kůži obličeje | Červená vaskulatura kůže obličejeSpojené státy
Klinické studie na Verapamil
-
University of PittsburghNational Institute of Mental Health (NIMH)Dokončeno
-
Benjamin BleierUkončeno
-
University Health Network, TorontoStaženo
-
Medical University of GrazJuvenile Diabetes Research FoundationNáborDiabetes mellitus, typ 1Spojené království, Belgie, Polsko, Rakousko, Francie, Německo, Itálie
-
Center Laboratories, Inc.UkončenoEpizodická bolest hlavySpojené království
-
AbbottDokončenoHypertenze | Diabetes
-
Jaeb Center for Health ResearchJuvenile Diabetes Research Foundation; University of Minnesota; Medtronic; DexCom... a další spolupracovníciDokončenoDiabetes typu 1Spojené státy
-
Menzies School of Health ResearchAga Khan University; University of Melbourne; Universitas Sumatera Utara; Ethiopian... a další spolupracovníciNáborVivax malárie | Malárie, Vivax | Plasmodium Vivax | Relaps malárieKambodža, Etiopie, Indonésie, Pákistán
-
Zealand University HospitalDokončenoObezita | Hypoglykémie | Chirurgická operace